Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement.

Beckman Coulter Life Sciences, announces the appointment of Joe Fox as President of the company effective immediately.

Since 1995, the Eppendorf Award for Young European Investigators, endowed with 20,000 EUR, has honored outstanding achievements in the field of biomedical research in Europe once a year.

BOC Sciences is pleased to announce its new Scholarship Program aimed at supporting college students pursuing degrees in chemistry-related fields.

Informed Genomics, the UK-based genomic testing laboratory delivering innovative ISO accredited services, has been selected by EMQN CIC to provide tumour profiling to support its quality assurance services.

Archer CGP research assays now enable homologous recombination deficiency (HRD) assessment for identification of key biomarkers critical for cancer research.

Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

Assay automation makes cutting-edge research more accessible to labs.

Transgene (Euronext Paris: TNG), announces the conversion into equity of 32,999,999.57 euros of debt, drawn down under the outstanding current account advance with its majority shareholder TSGH.